<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39313353</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1544-1717</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Season>Sep-Oct</Season></PubDate></JournalIssue><Title>Annals of family medicine</Title><ISOAbbreviation>Ann Fam Med</ISOAbbreviation></Journal><ArticleTitle>The Odyssey of HOMER: Comparative Effectiveness Research on Medication for Opioid Use Disorder During the COVID-19 Pandemic.</ArticleTitle><Pagination><StartPage>444</StartPage><EndPage>450</EndPage><MedlinePgn>444-450</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1370/afm.3149</ELocationID><Abstract><AbstractText>The usual challenges of conducting primary care research, including randomized trials, have been exacerbated, and new ones identified, during the COVID-19 pandemic. HOMER (Home versus Office for Medication Enhanced Recovery; subsequently, Comparing Home, Office, and Telehealth Induction for Medication Enhanced Recovery) is a pragmatic, comparative-effectiveness research trial that aims to answer a key question from patients and clinicians: What is the best setting in which to start treatment with buprenorphine for opioid use disorder for this patient at this time? In this article, we describe the difficult journey to find the answer. The HOMER study began as a randomized trial comparing treatment outcomes in patients starting treatment with buprenorphine via induction at home (unobserved) vs in the office (observed, synchronous). The study aimed to enroll 1,000 participants from 100 diverse primary care practices associated with the State Networks of Colorado Ambulatory Practices and Partners and the American Academy of Family Physicians National Research Network. The research team faced unexpected challenges related to the COVID-19 pandemic and dramatic changes in the opioid epidemic. These challenges required changes to the study design, protocol, recruitment intensity, and funding conversations, as well as patience. As this is a participatory research study, we sought, documented, and responded to practice and patient requests for adaptations. Changes included adding a third study arm using telehealth induction (observed via telephone or video, synchronous) and switching to a comprehensive cohort design to answer meaningful patient-centered research questions. Using a narrative approach based on the Greek myth of Homer, we describe here the challenges and adaptations that have provided the opportunity for HOMER to thrive and find the way home. These clinical trial strategies may apply to other studies faced with similar cultural and extreme circumstances.</AbstractText><CopyrightInformation>Â© 2024 Annals of Family Medicine, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zittleman</LastName><ForeName>Linda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>University of Colorado Department of Family Medicine, Aurora, Colorado Linda.Zittleman@cuanschutz.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Westfall</LastName><ForeName>John M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>University of Colorado Department of Family Medicine, Aurora, Colorado.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sofie</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>University of Colorado Department of Family Medicine, Aurora, Colorado.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lutgen</LastName><ForeName>Cory</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>AAFP National Research Network at the DARTNet Institute, Aurora, Colorado.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernald</LastName><ForeName>Douglas</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>University of Colorado Department of Family Medicine, Aurora, Colorado.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>Tristen L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>University of Colorado Department of Family Medicine, Aurora, Colorado.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hochheimer</LastName><ForeName>Camille J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>University of Colorado Department of Family Medicine, Aurora, Colorado.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>Melanie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>HOMER Community Advisory Council.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Felzien</LastName><ForeName>Maret</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>HOMER Community Advisory Council.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickinson</LastName><ForeName>L Miriam</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>University of Colorado Department of Family Medicine, Aurora, Colorado.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manning</LastName><ForeName>Brian K</ForeName><Initials>BK</Initials><AffiliationInfo><Affiliation>AAFP National Research Network at the DARTNet Institute, Aurora, Colorado.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>LeMaster</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>AAFP National Research Network at the DARTNet Institute, Aurora, Colorado.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nease</LastName><ForeName>Donald E</ForeName><Initials>DE</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>University of Colorado Department of Family Medicine, Aurora, Colorado.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Fam Med</MedlineTA><NlmUniqueID>101167762</NlmUniqueID><ISSNLinking>1544-1709</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>40D3SCR4GZ</RegistryNumber><NameOfSubstance UI="D002047">Buprenorphine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009292">Narcotic Antagonists</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002047" MajorTopicYN="Y">Buprenorphine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057186" MajorTopicYN="Y">Comparative Effectiveness Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009293" MajorTopicYN="Y">Opioid-Related Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058850" MajorTopicYN="Y">Opiate Substitution Treatment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011320" MajorTopicYN="N">Primary Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017216" MajorTopicYN="N">Telemedicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009292" MajorTopicYN="N">Narcotic Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003120" MajorTopicYN="N" Type="Geographic">Colorado</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">buprenorphine</Keyword><Keyword MajorTopicYN="N">clinical trials as topic</Keyword><Keyword MajorTopicYN="N">health services</Keyword><Keyword MajorTopicYN="N">opioid use disorder</Keyword><Keyword MajorTopicYN="N">pandemics</Keyword><Keyword MajorTopicYN="N">participatory research</Keyword><Keyword MajorTopicYN="N">practice-based research</Keyword><Keyword MajorTopicYN="N">primary care</Keyword><Keyword MajorTopicYN="N">vulnerable populations</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>4</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>23</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>5</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>21</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39313353</ArticleId><ArticleId IdType="pmc">PMC11419717</ArticleId><ArticleId IdType="doi">10.1370/afm.3149</ArticleId><ArticleId IdType="pii">22/5/444</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Homer. The Odyssey. In: Iliad of Homer and The Odyssey. Hutchins RM, ed. Adler MJ, assoc ed. Butler S, trans. Great Books of the Western World Series. Vol 4. Encyclopedia Britannica; 1952.</Citation></Reference><Reference><Citation>OâBrien EC, Sugarman J, Weinfurt KP, et al. . The impact of COVID-19 on pragmatic clinical trials: lessons learned from the NIH Health Care Systems Research Collaboratory. Trials. 2022; 23(1): 424. 10.1186/s13063-022-06385-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-022-06385-8</ArticleId><ArticleId IdType="pmc">PMC9123729</ArticleId><ArticleId IdType="pubmed">35597988</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledford H. The COVID pandemicâs lingering impact on clinical trials. Nature. 2021; 595(7867): 341-342. 10.1038/d41586-021-01569-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-021-01569-9</ArticleId><ArticleId IdType="pubmed">34183846</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook NL, Lauer MS.. Biomedical research COVID-19 impact assessment: lessons learned and compelling needs. National Academy of Medicine. Published Jul 26, 2021. 10.31478/202107e</Citation><ArticleIdList><ArticleId IdType="doi">10.31478/202107e</ArticleId><ArticleId IdType="pmc">PMC8486427</ArticleId><ArticleId IdType="pubmed">34611607</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle P.
Basic medical research took a hit during the pandemic. It might take years to recover. AAMC News. Published May
6, 2021. Accessed Feb 27, 2023. https://www.aamc.org/news-insights/basic-medical-research-took-hit-during-pandemic-it-might-take-years-recover</Citation></Reference><Reference><Citation>Sathian B, Asim M, Banerjee I, et al. . Impact of COVID-19 on clinical trials and clinical research: a systematic review. Nepal J Epidemiol. 2020; 10(3): 878-887. 10.3126/nje.v10i3.31622</Citation><ArticleIdList><ArticleId IdType="doi">10.3126/nje.v10i3.31622</ArticleId><ArticleId IdType="pmc">PMC7538012</ArticleId><ArticleId IdType="pubmed">33042591</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtrop JS, Davis MM.. Primary care research is hard to do during COVID-19: challenges and solutions. Ann Fam Med. 2022; 20(6): 568-572. 10.1370/afm2889</Citation><ArticleIdList><ArticleId IdType="doi">10.1370/afm2889</ArticleId><ArticleId IdType="pmc">PMC9705050</ArticleId><ArticleId IdType="pubmed">36443077</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasch F, Psarelli E-E, Herold R, et al. . The impact of COVID-19 on the initiation of clinical trials in Europe and the United States. Clin Pharmacol Ther. 2022; 111(5): 1093-1102. 10.1002/cpt.2534</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.2534</ArticleId><ArticleId IdType="pmc">PMC9015398</ArticleId><ArticleId IdType="pubmed">35090044</ArticleId></ArticleIdList></Reference><Reference><Citation>University of Oxford . A tale of three trials: the impact of COVID-19 on clinical research. Accessed Feb 27, 2023. https://www.ndph.ox.ac.uk/longer-reads/a-tale-of-three-trials-the-impact-of-covid-19-on-clinical-research</Citation></Reference><Reference><Citation>The University of Utah . Research response to COVID-19. Accessed Feb 27, 2023. https://coronavirus.utah.edu/research/</Citation></Reference><Reference><Citation>Association of American Medical Colleges . Examples of COVID-19 impacts on the research enterprise. Published Apr
2021. Accessed Feb 27, 2023. https://www.aamc.org/media/54391/download</Citation></Reference><Reference><Citation>Ramos S.
COVID-19âs impact felt by researchers: scientists, graduate students talk about conducting research during a pandemic. American Psychological Association. Published Mar
1, 2021. Accessed Feb 27, 2023. https://www.apa.org/science/leadership/students/covid-19-impact-researchers</Citation></Reference><Reference><Citation>University of Oxford, The Nuffield Department of Population Health . Creating clarity in a time of uncertainty, 2020. Accessed Feb 27, 2023. https://www.ndph.ox.ac.uk/files/news/ndph-covid-report-2020.pdf</Citation></Reference><Reference><Citation>Zittleman L, Curcjia K, Nease D, et al. . Increasing capacity for OUD treatment in rural primary care. Ann Fam Med. 2022; 20(1): 18-23. 10.1370/afm.2757</Citation><ArticleIdList><ArticleId IdType="doi">10.1370/afm.2757</ArticleId><ArticleId IdType="pmc">PMC8786417</ArticleId><ArticleId IdType="pubmed">35074763</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakko J, Svanborg KD, Kreek MJ, Heilig M.. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet. 2003; 361(9358): 662-668. 10.1016/S0140-6736(03)12600-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(03)12600-1</ArticleId><ArticleId IdType="pubmed">12606177</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JD, Grossman E, DiRocco D, Gourevitch MN.. Home buprenorphine/naloxone induction in primary care. J Gen Intern Med. 2009; 24(2): 226-232. 10.1007/s11606-008-0866-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-008-0866-8</ArticleId><ArticleId IdType="pmc">PMC2628995</ArticleId><ArticleId IdType="pubmed">19089508</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JD, Vocci F, Fiellin DA.. Unobserved âhomeâ induction onto buprenorphine. J Addict Med. 2014; 8(5): 299-308. 10.1097/ADM.0000000000000059</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ADM.0000000000000059</ArticleId><ArticleId IdType="pubmed">25254667</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohler NL, Li X, Kunins HV, et al. . Home- versus office-based buprenorphine inductions for opioid-dependent patients. J Subst Abuse Treat. 2010; 38(2): 153-159. 10.1016/j.jsat.2009.08.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsat.2009.08.001</ArticleId><ArticleId IdType="pmc">PMC2849656</ArticleId><ArticleId IdType="pubmed">19801178</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernald DH, Nease DE, Westfall JM, et al. . A randomized, parallel group, pragmatic comparative-effectiveness trial comparing medication-assisted treatment induction methods in primary care practice: the HOMER study protocol. PLoS One. 2023; 18(9): e0290388. 10.1371/journal.pone.0290388</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0290388</ArticleId><ArticleId IdType="pmc">PMC10490863</ArticleId><ArticleId IdType="pubmed">37682828</ArticleId></ArticleIdList></Reference><Reference><Citation>Etz RS, Solid CA, Gonzalez MM, Britton E, Stange KC, Reves SR.. Telemedicine in primary care: lessons learned about implementing health care innovations during the COVID-19 pandemic. Ann Fam Med. 2023; 21(4): 297-304. 10.1370/afm.2979</Citation><ArticleIdList><ArticleId IdType="doi">10.1370/afm.2979</ArticleId><ArticleId IdType="pmc">PMC10365867</ArticleId><ArticleId IdType="pubmed">37487734</ArticleId></ArticleIdList></Reference><Reference><Citation>Torgerson DJ, Sibbald B.. Understanding controlled trials. What is a patient preference trial? BMJ. 1998; 316(7128): 360. PMID: 9487173</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2665528</ArticleId><ArticleId IdType="pubmed">9487173</ArticleId></ArticleIdList></Reference><Reference><Citation>Olschewski M, Scheurlen H.. Comprehensive Cohort Study: an alternative to randomized consent design in a breast preservation trial. Methods Inf Med. 1985; 24(3): 131-134. PMID: 4033443</Citation><ArticleIdList><ArticleId IdType="pubmed">4033443</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmoor C, Olschewski M, Schumacher M.. Randomized and non-randomized patients in clinical trials: experiences with comprehensive cohort studies. Stat Med. 1996; 15(3): 263-271. 10.1002/(SICI)1097-0258(19960215)15:3&lt;263::AID-SIM165&gt;3.0.CO;2-K</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-0258(19960215)15:3&lt;263::AID-SIM165&gt;3.0.CO;2-K</ArticleId><ArticleId IdType="pubmed">8643884</ArticleId></ArticleIdList></Reference><Reference><Citation>United States Drug Enforcement Agency . Sharp increase in fake prescription pills containing fentanyl and meth. Published Sep
27, 2021. Accessed Sep 12, 2023. https://www.dea.gov/alert/sharp-increase-fake-prescription-pills-containing-fentanyl-and-meth</Citation></Reference><Reference><Citation>Suen LW. Rapid overlap initiation protocol using low dose buprenorphine for opioid use disorder treatment in an outpatient setting: a case series. J Addict Med. 2022; 16: 534-540. 10.1097/ADM.0000000000000961</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ADM.0000000000000961</ArticleId><ArticleId IdType="pmc">PMC11006272</ArticleId><ArticleId IdType="pubmed">35149614</ArticleId></ArticleIdList></Reference><Reference><Citation>Raheemullah A, Benhamou OM, Kuo J, Lembke A.. Buprenorphine microdosing cross tapers: a time for change. Int J Environ Res Public Health. 2022; 19(24): 16436. 10.3390/ijerph192416436</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph192416436</ArticleId><ArticleId IdType="pmc">PMC9778657</ArticleId><ArticleId IdType="pubmed">36554317</ArticleId></ArticleIdList></Reference><Reference><Citation>Herring AA, Vosooghi AA, Luftig J, et al. . High-dose buprenorphine induction in the emergency department for treatment of opioid use disorder. JAMA Network Open. 2021; 4(7): e2117128. 10.1001/jamanetworkopen.2021.17128</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.17128</ArticleId><ArticleId IdType="pmc">PMC8283555</ArticleId><ArticleId IdType="pubmed">34264326</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciccarone D. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. Curr Opin Psychiatry. 2021; 34(4): 344-350. 10.1097/YCO.0000000000000717</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/YCO.0000000000000717</ArticleId><ArticleId IdType="pmc">PMC8154745</ArticleId><ArticleId IdType="pubmed">33965972</ArticleId></ArticleIdList></Reference><Reference><Citation>Green LW. Making research relevant: if it is an evidence-based practice, whereâs the practice-based evidence? Fam Pract. 2008; 25(Suppl 1): i20-i24. 10.1093/fampra/cmn055</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/fampra/cmn055</ArticleId><ArticleId IdType="pubmed">18794201</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>